Dimensional Fund Advisors LP bought a new position in shares of Catalyst Biosciences Inc (NASDAQ:CBIO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 79,963 shares of the biopharmaceutical company’s stock, valued at approximately $372,000. Dimensional Fund Advisors LP owned approximately 1.88% of Catalyst Biosciences at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Virtu KCG Holdings LLC bought a new stake in Catalyst Biosciences in the 2nd quarter worth about $103,000. Bank of New York Mellon Corp bought a new stake in Catalyst Biosciences in the 2nd quarter worth about $107,000. Finally, Vanguard Group Inc. grew its position in Catalyst Biosciences by 294.1% in the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares in the last quarter. 31.47% of the stock is owned by institutional investors.
Shares of Catalyst Biosciences Inc (CBIO) opened at $7.02 on Wednesday. Catalyst Biosciences Inc has a 52-week low of $3.11 and a 52-week high of $21.30.
Catalyst Biosciences Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Want to see what other hedge funds are holding CBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Biosciences Inc (NASDAQ:CBIO).
Receive News & Ratings for Catalyst Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.